Sat, Apr 19, 2014, 1:13 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Given Imaging Ltd. (GIVN) Message Board

dubi_calmy 5 posts  |  Last Activity: Mar 23, 2014 12:16 PM Member since: Dec 6, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    premarket up .04..

    by starteam003 Mar 18, 2014 7:17 AM
    dubi_calmy dubi_calmy Mar 18, 2014 8:04 AM Flag

    Splendid news for parent company EMITF!!!

    Novartis in advanced talks to buy Gamida-Cell
    biomed

    18/03/2014, 12:06
    Gali Weinreb
    The stem cell developer could be acquired for up to $600 million.

    Sources inform ''Globes'' that Novartis AG (NYSE:NVS; LSE: NOV; SWX: NOVZ) is in advanced talks to acquire stem cell treatments developer Gamida-Cell Ltd. at a value of hundreds of millions of dollars. Under the deal, Novartis will pay several hundred millions dollars in a down payment for the company, and will pay hundreds of millions of dollars more in milestones for the company's products for a total of up to $600 million.

    Clal Biotechnology Industries Ltd. (TASE: CBI) owns 22% of Gamida-Cell and Elbit Medical Technologies Ltd. (TASE:EMTC) owns 31%. The two companies' parent companies will also benefit from the sale. Clal Biotech is controlled by Len Blavatnik's Access Industries Inc., and Elbit Medical Technologies is controlled by Elbit Imaging Ltd. (Nasdaq: EMITF; TASE: EMIT), which was seized earlier this year by York Capital Management LLC and Davidson Kempner Capital Management LLC from Mordechay Zisser.

    Although the acquisition talks are in a very advanced stage, Gamida-Cell has not wholly abandoned plans for an IPO on Wall Street. However, the valuation for the IPO is much less than the reported value of the acquisition, and that will be likely be the preferred option.

    Gamida Cell has proprietary technology for growing the number and density of stem cells within a specific blood sample. This capability could be a basis for all stem cell activity. The company seeks to enhance umbilical cord blood donations for implants to cure blood cancer in adults. Currently, umbilical cord blood can only be used for implant in people weighing less than 45 kilograms.

    Gamida-Cell's first product was jointly developed with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), but the US Food and Drug Administration (FDA) retroactively tightened clinical trial requirements rendering the product's development uneconomical. The company is developing what it says is an improved product in the same field. The product is undergoing clinical trials, and because of its expected improved efficacy, justifies the high development cost. Teva has no rights to this product, making the deal with Novartis possible.

  • Reply to

    here's hoping for a pop soon

    by starteam003 Mar 18, 2014 7:01 AM
    dubi_calmy dubi_calmy Mar 18, 2014 8:09 AM Flag

    Today, breaking resistance due to the news!!!

    Sentiment: Strong Buy

  • Reply to

    premarket up .04..

    by starteam003 Mar 18, 2014 7:17 AM
    dubi_calmy dubi_calmy Mar 18, 2014 8:44 AM Flag

    Fair chance for this to happen too!!!

    Sentiment: Strong Buy

  • Reply to

    a food for thought..

    by starteam003 Mar 23, 2014 10:56 AM
    dubi_calmy dubi_calmy Mar 23, 2014 12:14 PM Flag

    What got EMITF in trouble was a/bad timing b/too many financial commitments

  • Reply to

    who is Ron Hadassi?

    by starteam003 Mar 21, 2014 10:42 AM
    dubi_calmy dubi_calmy Mar 23, 2014 12:16 PM Flag

    He will, no doubt about that!!!

GIVN
29.980.00(0.00%)Feb 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Weibo Corporation
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT